Treatment in metastatic prostate cancer with hormone refractory
نویسندگان
چکیده
منابع مشابه
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 3) clinical benefits seen...
متن کاملManagement of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.
BACKGROUND: Prostate cancer is a significant health problem in the United States and is the focus of increasing attention in our society. With the aging of the US population, it is likely that prostate cancer will continue to grow in importance. The options for systemic therapy of metastatic prostate cancer should be familiar to physicians, including nonspecialists, whose patients seek their ad...
متن کاملhormone therapy in metastatic prostate cancer
only orchiectomy is still commonly used today either as a single therapy or in combination regimens. hypophysectomy & adrenalectomy showed such devastating effects on the endocrine equilibrium as to be inconsistent with an acceptable quality of life or even with survival. chemical adrenalectomy was also tried with drugs (eg. aminoglutethmide, spironolactone) leading to consequences superimposab...
متن کاملAchieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
The belief that hormone-refractory prostate cancer (HRPC) is a chemotherapy-resistant disease has been effectively refuted by the results of two recent randomized phase III trials. The TAX327 trial compared weekly docetaxel, every-3-weeks (Q3W) docetaxel, and Q3W mitoxantrone plus prednisone in 1,006 patients with HRPC, and results demonstrated that survival was significantly longer with a doce...
متن کاملthe effect of multiplicity of metastatic sites on hormone refractory prostate cancer
background : this study retrospectively evaluated the prognostic factors and treatment outcome of patients with hormone-refractory prostate cancer who received chemotherapy. methods :we reviewed records of hormone-refractory prostate cancer patients who received chemotherapy between december 2004 and may 2011 at the clinical oncology and nuclear medicine department, mansoura university and the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2008
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2008.06.054